Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study

J Am Coll Cardiol. 2012 Feb 28;59(9):854-5. doi: 10.1016/j.jacc.2011.10.896.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / physiopathology
  • Benzimidazoles / administration & dosage
  • Benzimidazoles / therapeutic use*
  • Dabigatran
  • Dose-Response Relationship, Drug
  • Electrocardiography
  • Embolism / etiology
  • Embolism / prevention & control*
  • Female
  • Follow-Up Studies
  • Heart Rate / drug effects
  • Humans
  • Male
  • Randomized Controlled Trials as Topic
  • Stroke / etiology
  • Stroke / prevention & control*
  • Tachycardia, Paroxysmal / drug therapy*
  • Tachycardia, Paroxysmal / physiopathology
  • Time Factors
  • Treatment Outcome
  • Warfarin / administration & dosage
  • Warfarin / therapeutic use*
  • beta-Alanine / administration & dosage
  • beta-Alanine / analogs & derivatives*
  • beta-Alanine / therapeutic use

Substances

  • Anticoagulants
  • Benzimidazoles
  • beta-Alanine
  • Warfarin
  • Dabigatran